Latest revenue
$44.2M
as of 2026-03-31
Latest net income
$-632.8M
as of 2026-03-31
Net margin
-1431.4%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $7.56B
- Enterprise value
- $7.56B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $12.43
- 52-wk low
- $1.95
- Beta
- —
- Shares out
- 1.05B
5-year trend
About IBRX
Business description and risk factors will appear here once IBRX's latest filing is fully ingested.
Profitability
Operating margin
-226.0%
90.3%Net margin
-310.2%
88.9%Return on equity
70.2%
17.0%Return on assets
-70.0%
35.2%Leverage
Debt / equity
-2.00×
12.3%Long-term debt / equity
-0.95×
0.9%Debt / assets
199.7%
12.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $44.2M | +167.6% | $-632.8M | -388.1% | -1431.4% |
Q4 2025 2025-12-31 | $38.3M | +407.0% | $-61.9M | -4.7% | -161.8% |
Q3 2025 2025-09-30 | $32.1M | +425.1% | $-67.3M | +21.6% | -209.8% |
Q2 2025 2025-06-30 | $26.4M | +2423.9% | $-92.6M | +31.2% | -350.3% |
Q1 2025 2025-03-31 | $16.5M | +41192.5% | $-129.6M | +3.3% | -784.9% |
Q4 2024 2024-12-31 | $7.6M | — | $-59.2M | — | -783.4% |
Q3 2024 2024-09-30 | $6.1M | +7346.3% | $-85.7M | +10.3% | -1404.0% |
Q2 2024 2024-06-30 | $1.0M | +2453.7% | $-134.6M | +2.4% | -12852.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on IBRX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$4.5M
Net activity
−$4.5M
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns IBRX
Institutional value
$707.2M
Total shares held
93.3M
Distinct holders
262
-7 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 26.3M | $202.1M | +745.2K (+2.9%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 16.3M | $125.2M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 15.1M | $116.0M | — | New |
| 4 | UBS Group AG | 2.9M | $22.6M | +949.3K (+47.6%) | Added |
| 5 | SEB Asset Management AB | 2.4M | $18.8M | — | New |
| 6 | VANGUARD FIDUCIARY TRUST CO | 2.1M | $16.3M | — | New |
| 7 | Private Advisor Group, LLC | 1.6M | $12.6M | +1.5M (+923.5%) | Added |
| 8 | FEDERATED HERMES, INC. | 1.4M | $10.6M | — | New |
| 9 | JPMORGAN CHASE & CO | 1.5M | $9.9M | +269.6K (+22.1%) | Added |
| 10 | Cetera Investment Advisers | 946.7K | $7.3M | +910.1K (+2483.3%) | Added |
| 11 | Nuveen, LLC | 879.6K | $6.7M | +246.5K (+38.9%) | Added |
| 12 | LPL Financial LLC | 864.6K | $6.6M | +406.6K (+88.8%) | Added |
| 13 | Bank of New York Mellon Corp | 831.4K | $6.4M | -50.9K (-5.8%) | Trimmed |
| 14 | Pictet Asset Management Holding SA | 830.1K | $5.6M | +796.5K (+2365.7%) | Added |
| 15 | Clearwater Capital Advisors, LLC | 717.5K | $5.5M | -127.6K (-15.1%) | Trimmed |
| 16 | JANE STREET GROUP, LLC | 704.2K | $5.4M | -13.5M (-95.0%) | Trimmed |
| 17 | ALLEN HOLDING INC /NY | 687.6K | $5.3M | +0 (+0.0%) | No change |
| 18 | Swiss National Bank | 682.4K | $5.2M | +30.0K (+4.6%) | Added |
| 19 | Kercheville Advisors, LLC | 643.1K | $4.9M | +59.0K (+10.1%) | Added |
| 20 | D.A. DAVIDSON & CO. | 558.2K | $4.3M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once IBRX's latest filing finishes processing.